Teresa A. Hillier, MD, MS; Kimberly K. Vesco, MD, MPH; Kathryn L. Pedula, MS; Tracy L. Beil, MS; Evelyn P. Whitlock, MD, MPH; David J. Pettitt, MD
Acknowledgment: The authors thank their expert reviewers for feedback and guidance, in particular Marie-Aline Charles, MD; David Hadden, MD; Boyd Metzger, MD; and Catherine Spong, MD. They also thank Martie Sucec and Kevin Lutz, MFA, for their editorial assistance; Taryn Cardenas for her technical assistance; and Paula Smith for her overall help with managing the project.
Grant Support: This study was conducted by the Oregon Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (contract 290-02-0024, task order 2).
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Reprints are available from the Agency for Healthcare Research and Quality Web site (www.preventiveservices.ahrq.gov).
Current Author Addresses: Drs. Hillier, Vesco, and Whitlock; Ms. Pedula; and Ms. Beil: The Center for Health Research, Kaiser Permanente Northwest, 3800 North Interstate Avenue, Portland, OR 97227.
Dr. Pettitt: Sansum Diabetes Research Institute, 2219 Bath Street, Santa Barbara, CA 93105.
In 2003, the U.S. Preventive Services Task Force concluded that evidence was insufficient to advise for or against routinely screening all pregnant women for gestational diabetes mellitus.
To review evidence about the benefits and harms of screening for gestational diabetes.
Databases (MEDLINE, Database of Abstracts of Reviews of Effects, Health Technology Assessment Database, National Institute for Health and Clinical Effectiveness, and Cochrane Library) were searched for reports published from January 2000 to 15 November 2007 (and from 1966 to 1999 for additional studies on screening at less than 24 weeks' gestation), citations in the 2003 evidence report, and studies identified through consultation of experts and searches of bibliographies.
English-language studies that used standard 1- or 2-step testing for gestational diabetes and that evaluated at least 1 of the following outcomes: neonatal mortality; brachial plexus injury; clavicular fracture; admission to a neonatal intensive care unit for hypoglycemia, hyperbilirubinemia, or the respiratory distress syndrome; maternal mortality; and preeclampsia or pregnancy-induced hypertension.
2 reviewers evaluated 1607 abstracts, critically appraised 288 articles, and qualitatively synthesized 13 studies.
No randomized, controlled trials that directly evaluated the risks and benefits of gestational diabetes screening were found. One good-quality randomized, controlled trial of treatment of mild gestational diabetes in a screening-detected population supported a reduction in serious neonatal complications and showed that gestational diabetes treatment also reduced the risk for gestational hypertension. Very limited evidence was found to evaluate early screening for gestational diabetes (before 24 weeks' gestation). Limited evidence suggests that serious maternal hypoglycemia is rare with treatment and that overall quality of life is not worse among women receiving gestational diabetes treatment compared with women not receiving treatment.
The literature is limited by lack of a consistent standard for screening or diagnosis of gestational diabetes.
Limited evidence suggests that gestational diabetes treatment after 24 weeks improves some maternal and neonatal outcomes. Evidence is even more sparse for screening before 24 weeks' gestation.
Hillier TA, Vesco KK, Pedula KL, et al. Screening for Gestational Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;148:766–775. doi: 10.7326/0003-4819-148-10-200805200-00009
Download citation file:
Published: Ann Intern Med. 2008;148(10):766-775.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism, Guidelines.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use